Table 3.
Propensity-score-matching subgroup analyses for difference in length of stay at hospitalization according to famotidine use using analysis-of-covariance model.
| Length of stay at hospitalization, day | No H2-blocker vs. Current famotidine use |
Other H2-blocker use vs. Current famotidine use |
Current famotidine use vs. Past famotidine use |
|---|---|---|---|
| Mean difference (95% CI) | Mean difference (95% CI) | Mean difference (95% CI) | |
| Crude | −1.42 (−3.81:0.96) | −0.91 (−3.52:1.70) | −6.20 (−14.30: 1.87) |
| Minimally adjusteda | −1.31 (−3.61:0.99) | −0.97 (−3.56:1.62) | −6.02 (−13.80:1.76) |
| Fully adjustedb | −1.15 (−3.41:1.10) | −1.07 (−3.66:1.52) | −4.39 (−12.20:3.46) |
CI, confidence interval.
Numbers in bold indicate significant differences (p < 0.05).
a
Minimally adjusted: adjustment for age and sex.
b
Fully adjusted: adjustment for age, sex, region of residence, history of diabetes mellitus, cardiovascular disease, cerebrovascular disease, COPD, hypertension, and chronic kidney disease, and Charlson comorbidity index, previous use of steroid, aspirin, metformin, PPI.